Implementation of Clinical Decision Support on Emergency Department Delivery of Human Rabies Immune Globulin.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
21
6
2022
pubmed:
22
6
2022
medline:
24
6
2022
Statut:
epublish
Résumé
Fatal human rabies infections can be prevented through appropriate rabies postexposure prophylaxis (PEP). Errors in patient selection and administration of human rabies immune globulin in the emergency department (ED) setting were identified in a previous study of rabies PEP administration. To test the a priori hypothesis that implementation of a rabies PEP bundle in the ED would improve full adherence to 6 human rabies immune globulin quality indicators compared with preimplementation controls. This quality improvement study was conducted in 15 EDs in a US multihospital health system. Patients who received human rabies immune globulin or rabies vaccine in the ED from January 2015 to June 2018 were included in the preimplementation control group and from December 2019 to November 2020 were included in the postimplementation intervention group. Data were analyzed in January 2021. The PEP bundle was implemented in December 2019 and consisted of electronic health record enhancements, including clinical decision support, ED staff education, and patient education. Full adherence to 6 human rabies immune globulin quality indicators: patient selection, dose, timing, infiltration into wounds, administration distant from rabies vaccine site, and administration that avoids the buttock. The study included 324 patients; 254 patients were in preimplementation group (mean [SD] age, 39 [21] years; 135 [53%] women) and 70 in the postimplementation group (mean [SD] age, 38 [19] years; 33 [47%] women). Most patients presented to EDs embedded in a community hospital (231 patients [71%]). Full adherence increased from 37% in the preimplementation group to 61% postimplementation (absolute increase, 24%; 95% CI, 11% to 37%; P < .001). Adherence improved for quality indicators for infiltration into wounds (137 of 254 patients [54%] to 50 of 70 patients [71%]; P = .009), administration distant from rabies vaccine site (180 of 254 [71%] to 58 of 70 [83%]; P = .04), and administration that avoids the buttock (168 of 254 [66%] to 58 of 70 [83%]; P = .007). No instances of sciatic nerve injury or compartment syndrome were observed. In this quality improvement study, implementation of a rabies PEP bundle was associated with improved patient selection and delivery of human rabies immune globulin in EDs across a multihospital health system. Although the bundle included ED staff education and patient discharge education, the observed improvement was likely driven by clinical decision support from the rabies PEP ED order set. Future research should evaluate implementation of this clinical decision support at other health systems.
Identifiants
pubmed: 35727583
pii: 2793378
doi: 10.1001/jamanetworkopen.2022.16631
pmc: PMC9214583
doi:
Substances chimiques
Immunoglobulins
0
Immunologic Factors
0
Rabies Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2216631Références
J Neurosurg. 1998 Jul;89(1):13-23
pubmed: 9647167
Vaccine. 2018 Sep 5;36(37):5500-5503
pubmed: 30107991
Am J Trop Med Hyg. 2006 Aug;75(2):363-4
pubmed: 16896149
Vaccine. 2007 Nov 1;25(44):7605-9
pubmed: 17905484
MMWR Recomm Rep. 2010 Mar 19;59(RR-2):1-9
pubmed: 20300058
Hum Vaccin Immunother. 2017 Apr 3;13(4):762-765
pubmed: 28277089
J Emerg Med. 1996 May-Jun;14(3):287-92
pubmed: 8782021
Hum Vaccin Immunother. 2020;16(1):51-60
pubmed: 31210569
J Pediatr. 1961 Feb;58:195-204
pubmed: 13705320
J Emerg Nurs. 2012 Jan;38(1):22-29
pubmed: 22226133
Ann Plast Surg. 2020 Aug;85(2S Suppl 2):S161-S165
pubmed: 32501839
Pediatrics. 1982 Dec;70(6):944-8
pubmed: 6755373
JAMA. 2000 Aug 23-30;284(8):1001-7
pubmed: 10944646
MMWR Recomm Rep. 1994 Jan 28;43(RR-1):1-38
pubmed: 8145710
Vaccine. 1989 Oct;7(5):478-9
pubmed: 2815983
Epidemiol Infect. 2021 Mar 18;149:e119
pubmed: 33734061
PLoS Negl Trop Dis. 2021 Jul 15;15(7):e0009461
pubmed: 34264942
J Travel Med. 2000 Jul-Aug;7(4):187-8
pubmed: 11003730
J Int Med Res. 2014 Aug;42(4):887-97
pubmed: 24920643
ANZ J Surg. 2021 Mar;91(3):415-419
pubmed: 33538101
Pharmacotherapy. 2021 Aug;41(8):644-648
pubmed: 34224157
Vaccine. 2019 Oct 3;37 Suppl 1:A128-A131
pubmed: 31395454
J Emerg Med. 2004 Jul;27(1):15-9
pubmed: 15219298
Hum Vaccin Immunother. 2016 Mar 3;12(3):837-42
pubmed: 26317441
Clin Infect Dis. 1996 Feb;22(2):228-32
pubmed: 8838177
J Trop Pediatr. 2021 Aug 27;67(4):
pubmed: 34549787
Hum Vaccin Immunother. 2021 Dec 2;17(12):5355-5360
pubmed: 35061550
MMWR Recomm Rep. 2008 May 23;57(RR-3):1-28
pubmed: 18496505
Vaccine. 2016 Jan 4;34(2):187-189
pubmed: 26626211
Ann Emerg Med. 2020 Nov;76(5):595-601
pubmed: 33008651